LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Determining The Dividend, If Approved At The AGM
Pursuant to the regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the 29th Annual General Meeting of the Company is scheduled to be held on Saturday, September 30, 2023 at 11:00 a.m. (IST) through video conferencing ("VC")/Other Audio-Visuals Means ("OAVM"). LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Publication of Notice. LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Rajanibhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclosed herewith the copies of newspaper publication with respect to the unaudited financial results (standalone & consolidated) of the company for the quarter ended on 30.06.2023. LINCOLN PHARMACEUTICALS LTD. - 531633 - Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30.06.2023.
Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended 30.06.2023 LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter Ended 30.06.2023.
Unaudited Standalone & Consolidated Financial Results of the Company for the Quarter ended 30.06.2023. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Board Meeting Intimation To Consider And Approve The Un-Audited Financial Results For The Quarter Ended On June 30, 2023.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2023 along with any other business, if any. LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We hereby submit the confirmation certificate as received from M/S Link Intime India Private Limited, Registrar & Share Transfer Agent for the Quarter Ended June, 2023.